摘要
目的探讨川芎嗪对慢性心力衰竭(CHF)患者氨基末端脑钠肽前体(NT-proBNP)水平的影响。方法将52例CHF患者随机分为治疗组27例和对照组25例。对照组仅予以常规治疗;治疗组在对照组治疗基础上加用川芎嗪治疗,疗程均为14d。2组治疗前、后分别采血检测并比较血清NT-proBNP水平。结果 2组治疗后NT-proBNP水平低于本组治疗前,且治疗组低于对照组,差异均有统计学意义(P<0.05和P<0.01)。结论 CHF患者血清NT-proBNP水平明显增高,在常规治疗基础上加用川芎嗪治疗可进一步降低心力衰竭患者血清NT-proBNP水平。
Objective To deserve the influence from Ligustrazine on serum NT-proBNP level of patients with chronic heart failure（CHF）. Methods 52 cases of CHF were divided into the test group（ n = 27 ） and the control group（ n = 25 ） randomly. For the test group, Ligustrazine and conventional western medicine approach was put into practice. As for the control group, only conventional approach was carried out. The treatment lasted 14 days and serum NT-proBNP level was measured be- fore and after the cure. Then the deviation of serum NT-proBNP level of two groups was analyzed respectively. Results NT-proBNP level of two groups descended remarkably, while NT-proBNP level of the test group descended even more （ P 〈 0.05 and P 〈 0.01 ）. Conclusion NT-proBNP level of patients with CHF is observably higher than the normal. And the implement of ligustrazine on the fundament of conventional cure could reduce NT-proBNP level of CHF more effectively.
出处
《临床合理用药杂志》
2012年第17期1-2,共2页
Chinese Journal of Clinical Rational Drug Use
